FDA Advisory Panel’s Review of Peptides Sparks Consumer Interest and Controversy

A recent hearing by the FDA advisory panel brought peptides into the spotlight. These experimental drugs have gained attention for their potential therapeutic benefits. The panel reviewed seven peptide therapies, endorsing all but one, despite concerns from FDA scientists.

Peptides like BPC-157, TB-500, and MOTS-c are popular injectables. However, making these compounds is illegal for pharmacies in the U.S. The FDA will review data to determine if compounding these peptides will be permitted.

Dr. Jessica Duncan from IVIM Health finds herself explaining to patients that the timeline for availability remains uncertain. Demand for peptides continues to grow, yet FDA approval is not guaranteed.

The typical rulemaking process by the FDA can take months or longer. However, it might be expedited due to high demand and advocacy from Health Secretary Robert F. Kennedy Jr.

“I think they are going to leverage options to make this a faster process,” says Jesse Dresser, an industry representative.

The peptides might be placed on a “Category One list,” allowing pharmacies to start production sooner while formal rules are established.

Despite pressure, the FDA must review the available data before these peptides hit the market. Legal challenges might arise if Kennedy uses authority to fast-track them without fulfilling typical safety protocols.

The panel might recommend against changing the status of these peptides due to insufficient large-scale human trials. Yet, the agency seems aware that these products are already circulating in the gray market.

Demand for peptides, widely marketed for muscle growth and injury recovery, often exceeds the level of scientific evidence available. Several years ago, the FDA’s restrictions on peptides fueled the gray market, where safety concerns prevail.

Unregulated sources offer peptides under the guise of “research purposes,” raising risks. “The gray market space is seedier than people think,” warns Dr. Haleem Mohammed from Gameday Men’s Health.

FDA officials highlighted difficulties in defining substances due to varied chemical compositions. The agency aims to ensure some safety level before widespread availability of these compounds.

If approved, peptides will require prescriptions but will be available from compounding pharmacies. These pharmacies create drugs to order rather than through mass production.

Compounding pharmacies would need time to source ingredients necessary for peptide production. “It might take two months, it might take nine months,” says Scott Brunner from the Alliance for Pharmacy Compounding.

Prescribing these peptides, prevalent among telehealth companies and med spas, may face apprehension from traditional medical practitioners. Many doctors remain cautious due to a lack of established guidelines from major medical associations.

Dr. Harmeet Narula emphasizes the importance of understanding that FDA panel recommendations do not equate to drug approval.